Targeted degradation of KRAS protein in non‐small cell lung cancer: Therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles
Drug Development Research · 2024-08 · 85 (5)
DOI: 10.1002/ddr.22241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 05.08.2024. Verfasst von Xiaowen Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, School of Pharmacy, Yantai University, Yantai, Shandong, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Liposomes, Lung Neoplasms, Proteolysis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: The authors would like to thank Yantai University School of Pharmacy for supplying the facility. This study was supported by Natural Science Foundation of Shan….
Abstract (Originalsprache)
The role of KRAS mutation in non‐small cell lung cancer (NSCLC) initiation and progression is well‐established. However, “undruggable” KRAS protein poses the research of small molecule inhibitors a significant challenge. Addressing this, proteolysis‐targeting chimeras (PROTACs) have become a cutting‐edge treatment method, emphasizing protein degradation. A modified ethanol injection method was employed in this study to formulate liposomes encapsulating PROTAC drug LC‐2 (LC‐2 LPs). Precise surface modifications using cell‐penetrating peptide R8 yielded R8‐LC‐2 liposomes (R8‐LC‐2 LPs). Comprehensive cellular uptake and cytotoxicity studies unveiled that R8‐LC‐2 LPs depended on concentration and time, showcasing the superior performance of R8‐LC‐2 LPs compared to normal liposomes. In vivo pharmacokinetic profiles demonstrated the capacity of DSPE‐PEG2000 to prolong the circulation time of LC‐2, leading to higher plasma concentrations compared to free LC‐2. In vivo antitumor efficacy research underscored the remarkable ability of R8‐LC‐2 LPs to effectively suppress tumor growth. This study contributed to the exploration of enhanced therapeutic strategies for NSCLC, specifically focusing on the development of liposomal PROTACs targeting the “undruggable” KRAS protein. The findings provide valuable insights into the potential of this innovative approach, offering prospects for improved drug delivery and heightened antitumor efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, School of Pharmacy, Yantai University, Yantai, Shandong, China.
- MabPlex International, Yantai, Shandong, China.
- Shandong Institute for Food and Drug Control, Jinan, Shandong, China.
ORCID-Profile: Sha Liu
Förderung
- The authors would like to thank Yantai University School of Pharmacy for supplying the facility. This study was supported by Natural Science Foundation of Shan…
Zitieren
APA
Wang, X., Su, L., Niu, C., Li, X., Wang, R., Li, B., Liu, S., & Xu, Y. (2024). Targeted degradation of KRAS protein in non‐small cell lung cancer: Therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles. Drug Development Research, 85(5). https://doi.org/10.1002/ddr.22241
Vancouver
Wang X, Su L, Niu C, Li X, Wang R, Li B, et al. Targeted degradation of KRAS protein in non‐small cell lung cancer: Therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles. Drug Development Research. 2024;85(5). doi:10.1002/ddr.22241
BibTeX
@article{Wang2024,
author = {Wang, Xiaowen and Su, Linyu and Niu, Chong and Li, Xiao and Wang, Ruijie and Li, Bo and Liu, Sha and Xu, Yuwen},
title = {Targeted degradation of KRAS protein in non‐small cell lung cancer: Therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles},
journal = {Drug Development Research},
year = {2024},
volume = {85},
number = {5},
doi = {10.1002/ddr.22241}
}
EUVIMED